natgillin/translations-raw huggingface dataset:
• redness, heat, unusual swelling of skin or joint 
• rdečina, toplota, nenavadno otekanje kože ali sklepa,
Cholesterol increased sJIA 
zvišan holesterol sJIA
No clinically significant hypersensitivity reactions associated with tocilizumab and requiring treatment discontinuation were reported. 
Klinično pomembnih preobčutljivostnih reakcij, povezanih s tocilizumabom, ki bi zahtevale prekinitev zdravljenja, ni bilo.
RoActemra is used to treat: 
Zdravilo RoActemra se uporablja za zdravljenje:
Results of the population PK analysis for sJIA and pJIA patients confirmed that body size is the only covariate which has an appreciable impact on the pharmacokinetics of RoActemra including elimination and absorption so that body-weight based dosing should be taken into consideration (see Tables 8 and 9). 
Rezultati populacijske farmakokinetične analize za bolnike s sJIA in pJIA so potrdili, da je velikost telesa edina spremenljivka, ki ima znaten vpliv na farmakokinetiko zdravila RoActemra, vključno z izločanjem in absorpcijo, tako da je treba upoštevati odmerjanje na osnovi telesne mase (glejte preglednici 8 in 9).
The non-clinical safety profile of RoActemra in the cynomolgus monkey does not suggest a difference between intravenous and subcutaneous routes of administration. 
Neklinične varnostne značilnosti zdravila RoActemrav opicah Cynomolgus ne kažejo na razlike med intravensko in subkutano potjo uporabe.
If either of these applies to you, tell a doctor. 
Če se kar koli od naštetega nanaša na vas, obvestite zdravnika.
IL-6 has been implicated in the pathogenesis of diseases including inflammatory diseases, osteoporosis and neoplasia. 
IL-6 je domnevno vpleten v patogenezo nekaterih bolezni, med drugim vnetnih bolezni, osteoporoze in neoplazem.
Following subcutaneous dosing in RA patients, the time to peak serum RoActemra concentrations tmax was 2.8 days. 
Po subkutanem odmerjanju pri bolnikih z revmatoidnim artritisom je bil čas do največje serumske koncentracije zdravila RoActemra tmax 2,8 dni.
• Do not press the green activation button yet. 
• Zelenega gumba za aktivacijo v tem trenutku še ne pritisnite.
Patients should be advised to immediately seek medical help if they experience signs and symptoms of hepatic injury. 
Bolnikom je treba svetovati, naj nemudoma poiščejo zdravniško pomoč, če se pojavijo znaki in simptomi okvare jeter.
Eighty five percent (64/75) of tocilizumab treated patients and 24.3% (9/37) of placebo treated patients achieved this endpoint. 
85 % (64/75) bolnikov, zdravljenih s tocilizumabom in 24,3 % (9/37) bolnikov, zdravljenih s placebom, je doseglo ta cilj.
• fluid retention (oedema) in the lower legs, weight increase 
• zadrževanje tekočine (edemi) v spodnjem delu nog, povečanje telesne mase,
• calcium channel blockers (e.g. amlodipine), used to treat raised blood pressure 
• zaviralce kalcijevih kanalčkov (npr. amlodipin), ki se uporabljajo za zdravljenje zvišanega krvnega tlaka,
Preparing for a RoACTEMRA Injection Find a comfortable space with a clean, flat, working surface. 
Priprava na injiciranje zdravila RoACTEMRA Poiščite udoben prostor s čisto, ravno delovno površino.
• Check the Window area to see that it is filled with the purple indicator (See Figure L). 
• Preverite okence in se prepričajte, da je napolnjeno z vijoličnim indikatorjem (glejte sliko L).
The MAH must agree the content and format of the educational material, together with a communication plan (including means of distribution), with the national competent authority prior to distribution of the educational material. 
Imetnik dovoljenja za promet se mora pred razdeljevanjem izobraževalnega gradiva s pristojnim nacionalnim organom dogovoriti glede njegove vsebine in oblike, skupaj z načrtom obveščanja
• Check the expiration date on the pre-filled pen box. 
• Preverite datum izteka roka uporabnosti na škatli napolnjenega injekcijskega peresnika
However, doses below 1025 mg of this medicine contain less than 23 mg sodium, so they are virtually sodium free. 
Vendar pa odmerki tega zdravila, ki so manjši od 1025 mg, vsebujejo manj kot 23 mg natrija in so torej praktično "brez natrija".
• Guidance on how to diagnose Macrophage Activation Syndrome in sJIA patients 
• smernice za diagnozo sindroma aktivacije makrofagov pri bolnikih s sJIA,
• Choose a different injection site for each new injection at least 1 inch (2.5cm) from the last area you injected. 
• Za vsako novo injiciranje izberite drugo mesto injiciranja, ki naj bo od zadnjega območja injiciranja oddaljeno najmanj 1 palec (2,5 cm).
• Keep pressing down on the plunger while you take the needle out of the skin at the same angle as inserted. 
• Bat še naprej potiskajte, medtem ko odstranite iglo iz kože pod enakim kotom, kot ste jo vstavili
NOTE: Once the needle-cap is removed, the syringe must be used immediately. 
OPOMBA: Potem ko pokrovček injekcijske igle odstranite, je treba napolnjeno injekcijsko brizgo uporabiti nemudoma.
• You should use a different place each time you give yourself an injection, at least three centimeters from the area you used for your previous injection. 
• Vsakič, ko si daste injekcijo, uporabite drugo mesto, vsaj tri centimetre oddaljeno od prejšnjega mesta injiciranja.
• To be sure the needle can be inserted correctly under the skin, pinch a fold of loose skin at the clean injection site with your free hand. 
• Da bi zagotovo pravilno vstavili iglo pod kožo, s prosto roko naredite kožno gubo na očiščenem mestu za injiciranje.
Infections with neutropenia have been reported. 
Poročali so o okužbah z nevtropenijo.
Suitability of the patient or parent/guardian for subcutaneous home use should be assessed and patients or parent/guardian instructed to inform a healthcare professional before administering the next dose if they experience symptoms of an allergic reaction. 
O primernosti bolnika ali njegovega starša/skrbnika za subkutano domačo uporabo je treba presoditi in bolnikom ali njihovim staršem/skrbnikom naročiti, da pred aplikacijo naslednjega odmerka obvestijo zdravstvenega delavca, če izkusijo simptome alergijske reakcije.
• any part of the syringe appears to be damaged 
• je kateri koli del napolnjene injekcijske brizge videti poškodovan.
• ciclosporin, used to suppress your immune system during organ transplants 
• ciklosporin, ki se uporablja za zaviranje imunskega sistema pri presaditvi organa,
• When the purple indicator has stopped moving, release the green button. 
• Ko se vijolični indikator ustavi, spustite zeleni gumb.
Choose and Prepare an Injection Site Choose an Injection Site 
Izberite in pripravite mesto injiciranja Izberite mesto injiciranja
Continued durable responses were seen for over 3 years in the open label extension studies I-V. 
Neprekinjene trajne odzive prek 3 let so opazili v odprtih, podaljšanih fazah študij I-V.
Allergic reactions during or after injection: 
Alergijske reakcije med injiciranjem ali po njem:
Twist and pull off the green cap with the other hand (See Figure E). 
Z drugo roko zasučite in potegnite zelen pokrovček (glejte sliko E).
• the medicine is any color besides colorless to yellowish 
• je zdravilo drugačne barve od brezbarvne do rumenkaste,
Dose adjustments due to laboratory abnormalities (sJIA and pJIA) 
Prilagoditev odmerka zaradi nenormalnih laboratorijskih vrednosti (sJIA in pJIA)
In an independent cohort of 15 patients (range: 9-75 years old) with axicabtagene ciloleucel-induced CRS, 53% responded. 
V neodvisni kohorti 15 bolnikov (razpon: 9 - 75 let) s CRS, ki ga je povzročil aksicabtagen ciloleucel, je odziv doseglo 53 % bolnikov.
• Stevens-Johnson syndrome (skin rash, which may lead to severe blistering and peeling of the skin) 
• Stevens-Johnsonov sindrom (kožni izpuščaj, ki lahko vodi do hudih mehurjev in luščenja kože),
Side effects in children and adolescents with sJIA or pJIA 
Neželeni učinki pri otrocih in mladostnikih s sJIA ali pJIA
• Risk of Hepatotoxicity 
• tveganje za hepatotoksičnost:
Action 
Ukrepanje
Allergic reactions during or after infusion: 
Alergijske reakcije med infuzijo ali po njej:
Cases of opportunistic infections have been reported. 
Opisani so bili primeri oportunističnih okužb.
TCZ + Placebo (SC) N = 163 
TCZ + placebo (s.c.) n = 163
Do not inject RoACTEMRA if the liquid is cloudy, discolored, or has lumps or particles in it because it may not be safe to use. 
Ne injicirajte zdravila RoACTEMRA, če je raztopina motna, drugačne barve ali so v njej prisotne grudice ali delci, ker morda ni varna za uporabo.
Impaired lung function may increase the risk for developing infections. 
Motnje v delovanju pljuč lahko povečajo tveganje za razvoj okužb.
• Hold the RoACTEMRA pre-filled pen firmly with one hand. 
• Napolnjeni injekcijski peresnik zdravila RoACTEMRA trdno držite z eno roko.
The safety profile of tocilizumab in the pediatric population is summarized in the sections on pJIA and sJIA below. 
Varnostni profil tocilizumaba pri pediatrični populaciji je povzet v spodnjih poglavjih za pJIA in sJIA.
At steady-state following a dose of 8 mg/kg every 4 weeks, the effective t1/2 decreased with decreasing concentrations within a dosing interval from 18 days to 6 days. 
V stanju dinamičnega ravnovesja po odmerku 8 mg/kg na 4 tedne se je efektivni t1/2 skrajševal z zniževanjem koncentracij v odmernem intervalu od 18 dni do 6 dni.
• Check that the pre-filled pen box is not damaged. 
• Preverite, da škatla napolnjenega injekcijskega peresnika ni poškodovana.
L-Histidine monohydrochloride monohydrate L-Arginine 
L-histidinijev monoklorid monohidrat L-arginin
Lift the pre-filled pen straight off of the injection site at a 90° angle to remove the needle from the skin. 
Napolnjeni injekcijski peresnik dvignite z mesta injiciranja pod kotom 90 °, da odstranite iglo iz kože.
After 12 weeks or at the time of escape, due to disease worsening, patients were treated in the open label phase at weight appropriate dosing. 
Po 12 tednih ali zaradi poslabšanja bolezni so bili bolniki zdravljeni v odprti fazi z odmerjanjem primernim telesni masi.
Continued durable responses were seen for over 3 years in the ongoing open label extension studies I-V. 
Neprekinjene trajne odzive prek 3 let so opazili v odprtih, podaljšanih fazah študij I-V, ki še potekajo.
Patients should inform their doctor immediately if they experience signs and symptoms of liver toxicity including tiredness, abdominal pain and jaundice. 
Bolniki morajo nemudoma obvestiti zdravnika, če se pri njih pojavijo znaki in simptomi jetrne toksičnosti, vključno z utrujenostjo, bolečino v trebuhu in zlatenico;
RoActemra is given by injection under the skin (subcutaneously). 
Zdravilo RoActemra se daje v obliki injekcije pod kožo (subkutano).
Storage 
Shranjevanje
• Preparation of injection/infusion 
• priprava injekcije/infuzije,
The proportion of patients with serious adverse events was balanced between the treatment groups (tocilizumab 11.7% vs. adalimumab 9.9%). 
Delež bolnikov z resnimi neželenimi učinki je bil med zdravljenima skupinama uravnotežen (tocilizumab 11,7 % v primerjavi z adalimumabom 9,9 %).
Check with your healthcare provider for instructions about the right way to throw away used syringes. 
Pri svojem zdravstvenem delavcu preverite, kako pravilno zavreči uporabljene napolnjene injekcijske brizge.
RoActemra contains the active substance tocilizumab, which is a protein made from specific immune cells (monoclonal antibody), that blocks the action of a specific protein (cytokine) called interleukin-6. 
Zdravilo RoActemra vsebuje učinkovino tocilizumab, ki je beljakovina, narejena iz specifičnih imunskih celic (monoklonsko protitelo), ki blokira delovanje posebne beljakovine (citokina), imenovane interlevkin-6.
• Wipe the injection site with an alcohol pad in a circular motion and let it air dry to reduce the chance of getting an infection. 
• Mesto injiciranja obrišite z alkoholno blazinico s krožnimi gibi in pustite, da se posuši, da zmanjšate možnost okužbe.
ACR responses in study SC-I (% patients) at Week 24 
Odzivi ACR v študiji SC-I (% bolnikov) v 24. tednu
Events reported during the infusion were primarily episodes of hypertension; events reported within 24 hours of finishing an infusion were headache and skin reactions (rash, urticaria). 
Učinki, opisani med infundiranjem, so bile predvsem epizode hipertenzije, učinki, opisani v 24 urah po koncu infundiranja, pa so bili glavobol in kožne reakcije (izpuščaj, urtikarija).
Driving and using machines This medicine can cause dizziness. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo lahko povzroči omotico.
Treatment with a murine analogue did not exert toxicity in juvenile mice. 
Zdravljenje z murinskim analogom ni predstavljalo toksičnosti za juvenilne miši.
Switching from 8 mg/kg intravenous once every 4 weeks to 162 mg subcutaneous once every week, will alter exposure in the patient. 
Prehod z 8 mg/kg intravenske oblike enkrat na 4 tedne na 162 mg subkutano enkrat na teden spremeni izpostavljenost pri bolniku.
Population pharmacokinetic analysis for pJIA patients showed body size related impact on linear clearance so that body-weight based dosing should be taken into consideration (see Table 9). 
Populacijska farmakokinetična analiza je pri bolnikih s pJIA pokazala, da velikost telesa vpliva na linearni očistek, zato je treba upoštevati odmerjanje na osnovi telesne mase (glejte preglednico 9).
Keep track of your next dose. 
Zabeležite si svoj naslednji odmerek.
3 This adverse reaction was identified through post marketing surveillance but not observed in controlled clinical trials. 
3 Ta neželeni učinek so zabeležili v spremljanju po prihodu zdravila na trg, v kontroliranih kliničnih preskušanjih pa ga niso opazili.
• The Patient Information Packs (to be given to patients by healthcare professionals) 
• izobraževalno gradivo za bolnike, ki ga bolniku izroči zdravstveni delavec,
No (N = 55) 
ne (n = 55)
Prescribers are reminded of the risk of false negative tuberculin skin and interferon-gamma TB blood test results, especially in patients who are severely ill or immunocompromised. 
Zdravniki, ki predpisujejo zdravilo RoActemra, naj se zavedajo, da obstaja tveganje za lažno negativni rezultat tuberkulinskega kožnega testa in krvnega gama-interferonskega tuberkulinskega testa, posebno pri bolnikih, ki so hudo bolni ali imunokompromitirani.
Pinching the skin is important to ensure that you inject under the skin (into fatty tissue) but not any deeper (into muscle). 
Kožna guba je pomembna, da zagotovite injiciranje pod kožo (v maščobno tkivo), a ne globlje (v mišico).
At one year in the open label extension phase the overall rate of serious infections remained stable at 11.3 per 100 patient years. 
Po enem letu je v odprti, podaljšani fazi celoten delež resnih okužb ostal stabilen pri 11,3 na 100 bolnik-let.
Exploratory Endpoints Annualized relapse rate, Week 52§ 
Eksplorativni opazovani dogodki Na leto preračunani delež recidivov, 52. teden§
No case of an overdose in the paediatric population has been observed. 
Pediatrična populacija Primerov prekomernega odmerjanja v pediatrični populaciji ni bilo.
The most serious ADRs were serious infections, complications of diverticulitis, and hypersensitivity reactions. 
Najbolj resni neželeni učinki so bile resne okužbe, zapleti divertikulitisa in preobčutljivostne reakcije.
• Details on how to report serious adverse reactions 
• navodilo, kako poročati resne neželene učinke.
The study consisted of a 52-week blinded period (Part 1), 
Študija je obsegala 52-tedensko slepo obdobje (1. del), ki mu je sledilo
Study III evaluated 623 patients who had an inadequate clinical response to MTX. 
Študija III je ocenila 623 bolnikov, ki se klinično niso dovolj odzvali na metotreksat.
At high serum concentrations, when total clearance of RoActemra is dominated by linear clearance, an effective t ½ of approximately 32 days was derived from the population parameter estimates. 
Pri velikih koncentracijah v serumu, ko v celotnem očistku zdravila RoActemra prevladuje linearni očistek, so na podlagi populacijskih ocen parametra ugotovili efektivni t1/2 približno 32 dni.
Due to the dependence of total clearance on RoActemra serum concentrations, the half-life of RoActemra is also concentration-dependent and varies depending on the serum concentration level. 
Zaradi odvisnosti celotnega očistka od koncentracije zdravila RoActemra v serumu je tudi razpolovni čas zdravila RoActemra odvisen od koncentracije in se spreminja s koncentracijo zdravila v serumu.
Part I consisted of a 16-week active tocilizumab treatment lead-in period (n=188) followed by Part II, a 24-week randomized double-blind placebo-controlled withdrawal period (n=163), followed by Part III, a 64-week open-label period. 
V I. delu je bilo 16-tedensko aktivno uvajalno zdravljenje s tocilizumabom (n = 188), sledil je II., 24-tedenski randomizirani, dvojno slepi, s placebom kontrolirani del (n = 163) in III., 64-tedenski odprti del.
There are no adequate data from the use of RoActemra in pregnant women. 
Ni zadostnih podatkov o uporabi zdravila RoActemra pri nosečnicah.
• Do not use the pre-filled pen through clothing. 
• Napolnjenega injekcijskega peresnika ne uporabljajte skozi oblačila.
Keep the green button pressed in and continue holding the pre-filled pen pressed firmly against your skin (See Figure J). 
Še naprej pritiskajte zeleni gumb za aktivacijo in držite napolnjeni injekcijski peresnik trdno pritisnjen na kožo (glejte sliko J).
The safety profile of RoActemra across these indications remains similar and undifferentiated. 
Varnostne značilnosti zdravila RoActemra pri teh indikacijah so podobne in se ne razlikujejo.
- to address the risk that patients using RoActemra may develop serious hepatic injury. 
- da opozori na tveganje, da lahko zdravilo RoActemra povzroči resno okvaro jeter.
The safety profile of subcutaneous RoActemra was also evaluated in 52 paediatric patients with pJIA. 
Varnostni profil subkutanega zdravila RoActemra je bil ovrednoten tudi pri 52 pediatričnih bolnikih s pJIA.
• Dispose of the full container as instructed by your healthcare provider or pharmacist. 
• Napolnjen zabojnik odstranite po navodilih zdravstvenega delavca ali farmacevta.
Clinical response 
Klinični odziv
Two subcutaneous doses of RoActemra (162 mg every week and 162 mg every other week) were compared to two different placebo control groups randomised 2:1:1:1. 
Dva subkutana odmerka zdravila RoActemra (162 mg vsak teden in 162 mg vsak drugi teden) so primerjali z dvema različnima kontrolnima skupinama s placebom; bolniki so bili randomizirani v razmerju 2:1:1:1.
Tell your doctor if you are taking any other medicines (or your child is, if they are the patient), or have recently taken any. 
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli zdravilo (ali vaš otrok, če je on bolnik).
• If you have cancer, tell your doctor. 
• Če imate raka, morate to povedati svojemu zdravniku.
Patients randomized to tocilizumab had fewer ACR30 flares and higher overall ACR responses than patients receiving placebo regardless of a history of prior biologic use. 
Pri bolnikih, randomiziranih v skupino s tocilizumabom, je bilo manj poslabšanj ACR 30, celokupni odzivi ACR pa so bili višji kot pri bolnikih, ki so prejemali placebo, ne glede na predhodno uporabo bioloških zdravil.
• Prevention of medical errors and injection/infusion reactions 
• preprečevanje napak pri uporabi zdravila in reakcij, povezanih z injiciranjem/infundiranjem,
Seventeen (24%) tocilizumab treated patients versus 1 (3%) placebo patient were able to reduce their dose of corticosteroid by at least 20% without experiencing a subsequent JIA ACR30 flare or occurrence of systemic symptoms to week 12 (p=0.028). 
Sedemnajstim (24 %) bolnikom, ki so se zdravili s tocilizumabom, v primerjavi z 1 (3 %) bolnikom, ki je prejemal placebo, so lahko zmanjšali odmerek kortikosteroida za najmanj 20 % brez posledičnega poslabšanja merila JIA ACR 30 ali pojava sistemskih simptomov do 12. tedna (p = 0,028).
• Monitoring of the patient for injection/infusion reactions 
• spremljanje bolnika zaradi reakcij, povezanih z injiciranjem/infundiranjem,
• The active substance is tocilizumab. 
• Učinkovina je tocilizumab.
If the pre-filled pen does not reach room temperature, this could cause your injection to feel uncomfortable and it could take longer to inject. 
Če napolnjeni injekcijski peresnik ne doseže sobne temperature, lahko to povzroči, da injiciranje občutite kot neprijetno in le-to morda traja dlje.
A change in dose should only be based on a consistent change in the patient's body weight over time. 
Sprememba odmerka mora temeljiti na spremembi bolnikove telesne mase v določenem obdobju.
However, RoActemra can be given alone if your doctor determines that methotrexate is inappropriate. 
Vendar je mogoče zdravilo RoActemra uporabljati tudi samostojno, če vaš zdravnik presodi, da metotreksat za vas ni primeren.
• Clean the chosen injection site area using the alcohol pad (See Fig. C), to reduce the risk of infection. 
• Izbrano mesto injiciranja očistite z alkoholnim zložencem (glejte sliko C), da zmanjšate tveganje za okužbe.
Yes (N = 27) 
da (n = 27)
Table 7: Efficacy Results for Study VI (WA19924) ADA + Placebo (IV) N = 162 
Rezultati učinkovitosti za študijo VI (WA19924) ADA + placebo
The needle shield will then move out and lock into place covering the needle (See Figure L). 
Zaščita za iglo se bo nato pomaknila in zaprla iglo (glejte sliko L).
Patients (which includes younger children with sJIA or pJIA who may be less able to communicate their symptoms) and parents/guardians of sJIA or pJIA patients, should be instructed to contact their healthcare professional immediately when any symptoms suggesting infection appear, in order to assure rapid evaluation and appropriate treatment. 
Bolnikom (tudi mlajšim otrokom s sJIA ali pJIA, ki še ne znajo dobro sporočati svojih simptomov) in staršem/skrbnikom bolnikov s sJIA ali pJIA morate naročiti, naj se nemudoma posvetujejo z zdravnikom, če se pojavi kakršen koli simptom okužbe, da bodo deležni hitre ocene stanja in ustreznega zdravljenja.
• Take the box containing the syringe out of the refrigerator and open the box. 
• Vzemite škatlo z napolnjeno injekcijsko brizgo iz hladilnika in jo odprite.
Forty eight percent (48.1%, 39/81) of the patients treated with placebo flared compared with 25.6% (21/82) of tocilizumab treated patients. 
48,1 % (39/81) bolnikih, ki so se zdravili s placebom, v primerjavi s 25,6 % (21/82) bolnikov, ki so se zdravili s tocilizumabom.
If you have any questions or concerns about your RoACTEMRA pre-filled pen, talk to your healthcare provider familiar with RoACTEMRA. 
Če imate kakršna koli vprašanja ali pomisleke glede napolnjenega injekcijskega peresnika z zdravilom RoACTEMRA, se obrnite na zdravstvenega delavca, ki pozna zdravilo RoACTEMRA.
For storage conditions of the diluted medicinal product see section 6.3. 
Za pogoje shranjevanja razredčenega zdravila glejte poglavje 6.3.
Other medicines and RoActemra 
Druga zdravila in zdravilo RoActemra
• Dose calculation (RA, sJIA and pJIA patients), preparation of infusion and infusion rate 
• izračun odmerka (bolniki z revmatoidnim artritisom, sJIA in pJIA), priprava infuzije in hitrost infundiranja,
For SF-36, the mean change from baseline at week 24 in the mental component score was 6.22 for the subcutaneous arm and 6.54 for the intravenous arm, and for the physical component score was also similar with 9.49 for the subcutaneous arm and 9.65 for the intravenous arm. 
Po SF-36 je bila povprečna sprememba od izhodiščne vrednosti v 24. tednu za mentalno komponento ocene 6,22 v subkutani skupini in 6,54 v intravenski skupini, podobna je bila tudi za fizično komponento ocene: 9,49 v subkutani skupini in 9,65 v intravenski skupini.
Such reactions may be more severe, and potentially fatal in patients who have experienced hypersensitivity reactions during previous infusions even if they have received premedication with steroids and antihistamines. 
Tovrstne reakcije so lahko hujše in morebiti tudi smrtne pri bolnikih, pri katerih so se preobčutljivostne reakcije pojavile med predhodnimi infundiranji, tudi če so le-ti prejeli premedikacijo s steroidi in antihistaminiki.